Anheart Therapeutics Is A Clinical Stage Biopharmaceutical Company Founded In 2018Based In New York Citythe Company Focuses On Developing Precision Oncology Therapeutics That Target Specific Genetic Mutations In Various Cancersincluding Non Small Cell Lung Cancergliomaand Cholangiocarcinomaanheart Leverages Its Expertise In Clinical Research And Product Registration To Advance Its Drug Pipeline The Company S Key Products Include Taletrectiniba Next Generation Ros1 Inhibitor Currently In Pivotal Phase 2 Trials For Ros1 Positive Non Small Cell Lung Cancerand Safusideniba Midh1 Inhibitor Being Evaluated In A Phase 2 Trial For Idh1 Mutant Gliomaboth Therapeutics Aim To Inhibit Specific Proteins Or Pathways Involved In Cancer Progressionaligning With Anheart S Commitment To Precision Oncologyin March 2024Anheart Was Acquired By Nuvation Bio In An All Stock Transaction
